For the year ending 2025-12-31, LGNYZ had $102,620K increase in cash & cash equivalents over the period. $48,907K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | 124,453 |
| Gain on sale of pelican | 0 |
| Change in estimated fair value of contingent liabilities | -860 |
| Depreciation of fixed assets and amortization of intangible assets | 33,775 |
| Gain from short-term investments | 18,433 |
| (gain) loss from change in fair value of equity method investments and other investments | 90,670 |
| Loss from equity method investment in primrose bio | 0 |
| Gain on pelthos transaction | 53,072 |
| Accretion of premium on short-term investments, net | 4,958 |
| Amortization of debt discount and issuance fees | 1,273 |
| Loss (gain) on derivative instruments | 1,022 |
| Non-cash income from financial royalty assets | 8,620 |
| Cecl adjustment to financial royalty assets | -922 |
| Impairment loss of financial royalty assets | 6,197 |
| Lease amortization expense | 1,942 |
| Share-based compensation | 46,849 |
| Deferred income taxes, net | -22,684 |
| Other | 1,688 |
| Accounts receivable, net | 21,737 |
| Inventory | -4,988 |
| Other economic rights | 0 |
| Accounts payable and accrued liabilities | 5,882 |
| Income taxes receivable and payable | -2,667 |
| Deferred revenue | -578 |
| Other assets and liabilities | 3,887 |
| Net cash provided by operating activities | 49,359 |
| Acquisition of financial royalty assets | 10,862 |
| Acquisition of royalty receivables | 813 |
| Proceeds from financial royalty assets | 10,261 |
| Purchases of derivatives | 13,792 |
| Purchases of property and equipment | 452 |
| Purchases of short-term investments | 726,713 |
| Proceeds from sale of short-term investments | 159,584 |
| Proceeds from maturity of short-term investments | 217,700 |
| Cash outflow on deconsolidation of lnhc, inc | 8,085 |
| Cash paid for investment in primrose bio | 0 |
| Cash paid for other investments | 3,847 |
| Net cash paid for acquisitions | 0 |
| Cash paid for the agenus transaction | 0 |
| Cash paid for apeiron acquisition, net of cash received | 0 |
| Cash paid for invios investment | 303 |
| Net proceeds from viking share collar and viking share put | 0 |
| Net cash used in investing activities | -377,322 |
| Gross proceeds from issuance of 2030 convertible senior notes | 460,000 |
| Debt discount and payment of debt issuance cost | 15,528 |
| Purchase of 2030 convertible senior notes hedge | 113,250 |
| Proceeds from issuance of warrants | 67,390 |
| Repurchase of common stock | 15,000 |
| Proceeds from common stock issuance, net of commissions and fees | 0 |
| Repayment of 2023 notes at maturity | 0 |
| Payments under finance lease obligations | 27 |
| Payments to cvr holders | 174 |
| Net proceeds from stock option exercises and espp | 47,501 |
| Taxes paid related to net share settlement of equity awards | 9,599 |
| Proceeds from pelthos investors bridge loans | 6,910 |
| Net cash provided by (used) in financing activities | 428,223 |
| Effect of exchange rate changes on cash and cash equivalents | 2,360 |
| Net increase (decrease) in cash and cash equivalents | 102,620 |
| Cash and cash equivalents at beginning of year | 72,307 |
| Cash and cash equivalents at end of year | 174,927 |
LIGAND PHARMACEUTICALS INC (LGNYZ)
LIGAND PHARMACEUTICALS INC (LGNYZ)